DGAP-News: Abivax phase 3 program with obefazimod in ulcerative colitis progresses with US IRB approval

DGAP-News: ABIVAX / Key word(s): Study
Abivax phase 3 program with obefazimod in ulcerative colitis progresses with US IRB approval

04.08.2022 / 18:00
The issuer is solely responsible for the content of this announcement.


ABIVAX PHASE 3 PROGRAM WITH...
Quelle: Börse Online RSS Feed